“We are very excited to join forces with Neuraxpharm. The team has built one of the most relevant European players in the CNS field.”
Dr. Jörg Rockenhäuser - Partner and Chairman of DACH at Permira

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (“CNS”). Neuraxpharm develops and commercialises value-added medicines for patients suffering from chronic neurological and psychiatric disorders, including epilepsy, Parkinson’s, Alzheimer’s, Multiple Sclerosis, depression, and psychosis.

With one of the broadest and most diversified product portfolios of over 130 CNS molecules, a strong medical reputation and deep CNS experience, the company holds leading positions in its core markets, Germany and Spain, and across Europe in many of its CNS molecules.

The Company also enjoys a strong track record of successfully in-licensing innovative CNS drugs and has emerged as a go-to commercialization & distribution partner in Europe.